References
- Flaherty K R, Saint S, Fendrick A M, Martinez F J. The spectrum of acute bronchitis. Using baseline factors to guide empirical therapy. Postgrad Med 2001; 109(2)39–47, [PUBMED], [INFOTRIEVE], [CSA]
- Pauwels R A, Buist A S, Calverley P M, Jenkins C R, Hurd S S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001; 163(5)1256–1276, [PUBMED], [INFOTRIEVE], [CSA]
- Benson V, Marano M A. Current estimates from the National Health Interview Survey, 1995. Vital Health Stat 1998; 10(199)1–428
- Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management. J Antimicrob Chemother 1999; 43(suppl A)97–105, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Halpern M T, Higashi M K, Bakst A W, Schmier J K. The economic impact of acute exacerbations of chronic bronchitis in the United States and Canada: a literature review. J Manag Care Pharm 2003; 9(4)353–359, [PUBMED], [INFOTRIEVE]
- Smith M D, Mcghan W F. Breathing lessons: the costs of COPD. Bus Health 1996; 14(10)79–80; 82, [PUBMED], [INFOTRIEVE]
- Sin D D, Stafinski T, Ng Y C, Bell N R, Jacobs P. The impact of chronic obstructive pulmonary disease on work loss in the United States. Am J Crit Care Med 2002; 165: 704–707, [CSA]
- Trupin L, Earnest G, San Pedro M, Balmes J R, Eisner M D, Yelin E, Katz P P, Blanc P D. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 2003; 22(3)462–469, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Francis R S, Spicer C C. Chemotherapy in chronic bronchitis: influence of daily penicillin and tetracycline on exacerbations and their cost. A report to the Research Committee of the British Tuberculosis Association by their Chronic Bronchitis Subcommittee. Br Med J 1960; 1: 297–303
- Alderson M R. Data on sickness absence in some recent publications of the Ministry of Pensions and National Insurance. Br J Prev Soc Med 1967; 21(1)1–6, [PUBMED], [INFOTRIEVE]
- Lops M, Somma M, Bottero A. Index of absenteeism from work due to recurrence of chronic bronchitis. G Ital Mal Torace 1971; 25(4)189–192, [PUBMED], [INFOTRIEVE]
- Grandjean E M, Berthet P H, Ruffmann R, Leuenberger P. Cost‐effectiveness analysis of oral N‐acetylcysteine as a preventive treatment in chronic bronchitis. Pharmacol Res 2000; 42(1)39–50, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Halpern M T, Palmer C S, Zodet M, Kirsch J. Cost‐effectiveness of gemifloxacin: results from the GLOBE study. Am J Health‐Syst Pharm 2002; 59(14)1357–1365
- Li‐Mcleod J, Perfetto E M. Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin. Manag Care Interface 2001; 14(2)52–59, [CSA]
- Niroumand M, Grossman R F. Airway infection. Infect Dis Clin North Am 1998; 12(3)671–688, [PUBMED], [INFOTRIEVE], [CSA]
- British Medical Research Council. Chronic bronchitis and occupation. Br Med J 1966; 5479: 101–102
- Incapacity for work. Br Med J 1966; 5479: 61–62
- Clark R A, Anderson J, Skinner C. The bronchitic patient: a study of his employment problems. Br J Dis Chest 1981; 75(1)31–39, [PUBMED], [INFOTRIEVE]
- Pechère J C, Lacey L. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 2000; 45: 19–24, [CROSSREF], [CSA]
- Perfetto E M, Mullins C D, Subedi P, Li‐McLeod J. Selection of clinical, patient‐reported, and economic end points in acute exacerbation of chronic bronchitis. Clin Ther 2001; 23(10)1747–1772, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Halpern M T, Shikiar R, Rentz A M, Khan Z M. Impact of smoking status on workplace absenteeism and productivity. Tob Control 2001; 10(3)233–238, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]